La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Cepton a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Cepton..

Cepton (NASDAQ:CPTN) Azioni, Catena delle Opzioni

Cepton

Cepton Inc provides lidar-based solutions for a range of markets such as automotive, smart cities, smart spaces and smart industrial applications. The company's patented MMT-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.

CAMDEN PROPERTY REIT ORD

Cepton Inc

WIIM

RVLV

Revolve Group shares are trading higher after the company reported better-than-expected Q3 financial results.

McVey has agreed to remain as the Chairman of the Board of Directors of MarketAxess Limited, the Company's international holding company.

News

Management

MKTX

MarketAxess Founder And Executive Chairman Rick Mcvey To Retire At Year-End; Carlos Hernandez Elected As Next Chairman

The quarterly dividend of $0.55 per common share is payable November 29, 2024, to stockholders of record at the close of business on November 15, 2024.&nbsp;

Dividends

Health Care

General

Cencora Declared A Quarterly Dividend Of $0.55 Per Common Share, An 8% Increase In Its Quarterly Dividend Rate From $0.51 Per Common Share

Guidance

Kennametal Sees Q2 Revenues Of $480M-$500M Vs. $492.97M Estimate; And Adjusted EPS Of $0.20-$0.30 Vs. $0.27 Estimate

HC Wainwright &amp; Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIU#NASDAQ">ACIU</a>) with a Buy and maintains $16 price target.

Price Target

Reiteration

Analyst Ratings

ACIU

HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) reported quarterly earnings of $3.34 per share which beat the analyst consensus estimate of $3.22 by 3.73 percent. This is a 16.78 percent increase over earnings of $2.86 per share from the same period last year. The company reported quarterly sales of $79.05 billion which beat the analyst consensus estimate of $77.65 billion by 1.80 percent. This is a 14.70 percent increase over sales of $68.92 billion the same period last year.

Earnings

Cencora Q4 2024 Adj EPS $3.34 Beats $3.22 Estimate, Sales $79.05B Beat $77.65B Estimate

Bookings were $3.82 billion, representing a book-to-bill ratio of 104.4% or 109.3% on a trailing twelve-month basis.&nbsp;
Bookings were $3.82 billion, representing a book-to-bill ratio of 104.4% or 109.3% on a trailing twelve-month basis.
 &nbsp;

CGI's Q4 Bookings Were $3.82B For A Book-To-Bill Ratio Of 104.4%

The Company now expects its fiscal 2024 organic net sales and reported net sales outlooks towards the lower end of its previously stated ranges of organic net sales growth versus the prior year of -3% to -1% and reported net sales growth versus the prior year of -5% to -3%.&nbsp;

PRGO

Perrigo Now Expects FY24 Organic Net Sales And Reported Net Sales Outlooks Towards Lower End Of Its Previously Stated Ranges

Kennametal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMT#NYSE">KMT</a>) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $0.26 by 11.54 percent. The company reported quarterly sales of $481.948 million which missed the analyst consensus estimate of $484.074 million by 100.00 percent. This is a 100.00 percent decrease over sales of $492.476 million the same period last year.

Earnings Beats

Earnings Misses

Kennametal Q1 2025 Adj. EPS $0.29 Beats $0.26 Estimate, Sales $481.948M Miss $484.074M Estimate

GPUS

Hyperscale Data Announced That It Plans To Issue A $16.25M Stated Value Special Dividend of 10% Series E Cumulative Redeemable Perpetual Preferred Stock

Perrigo Reaffirms FY24 Adjusted EPS Outlook Of $2.50 - $2.65, Est $2.57

CVS shares are trading higher following a Q3 revenue beat.

Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) reported quarterly losses of $(2.44) per share which missed the analyst consensus estimate of $(1.01) by 141.58 percent. The company reported quarterly sales of $1.335 billion which beat the analyst consensus estimate of $1.329 billion by 0.44 percent.

LINE

Lineage Q3 2024 GAAP EPS $(2.44) Misses $(1.01) Estimate, Sales $1.335B Beat $1.329B Estimate

CGI Q4 2024 Adj. EPS C$1.92 Beats C$1.91 Estimate, Sales C$3.660B Beat C$3.609B Estimate

Perrigo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) reported quarterly earnings of $0.81 per share which missed the analyst consensus estimate of $0.82 by 1.22 percent. This is a 26.56 percent increase over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $1.09 billion which missed the analyst consensus estimate of $1.13 billion by 3.29 percent. This is a 3.20 percent decrease over sales of $1.12 billion the same period last year.

Perrigo Q3 2024 Adj EPS $0.81 Misses $0.82 Estimate, Sales $1.09B Miss $1.13B Estimate

Transaction Details
Cencora will acquire RCA for approximately $4.6 billion in cash, subject to a customary working capital and net-debt adjustment. RCA's affiliated practices, physicians and management will retain a minority interest in RCA, with Cencora holding approximately 85% ownership in RCA upon closing. Additionally, Cencora will potentially pay up to $500 million in aggregate contingent consideration in fiscal year 2027 and fiscal year 2028, subject to the successful completion of certain predefined business objectives.

Cencora Has Agreed To Acquire Retina Consultants Of America From Webster Equity Partners For Approximately $4.6B In Cash

Benchmark analyst David Williams reiterates Alpha &amp; Omega (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOSL#NASDAQ">AOSL</a>) with a Buy and maintains $40 price target.

AOSL

Benchmark Reiterates Buy on Alpha & Omega, Maintains $40 Price Target

MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $1.83 by 3.83 percent. The company reported quarterly sales of $206.715 million which beat the analyst consensus estimate of $206.245 million by 0.23 percent. This is a 19.99 percent increase over sales of $172.284 million the same period last year.

MarketAxess Holdings Q3 2024 GAAP EPS $1.90 Beats $1.83 Estimate, Sales $206.715M Beat $206.245M Estimate

CVS Health Q3 2024 Adj. EPS $1.09 Misses $1.53 Estimate, Sales $95.428B Beat $92.747B Estimate

Regis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGS#NYSE">RGS</a>) reported quarterly losses of $(0.36) per share. This is a 160 percent decrease over earnings of $0.60 per share from the same period last year. The company reported $46.06 million in sales this quarter. This is a 13.70 percent decrease over sales of $53.37 million the same period last year.

Regis Q1 EPS $(0.36) Down From $0.60 YoY, Sales $46.06M Down From $53.37M YoY

The latest announcement is out from Cepton (CPTN). Cepton, Inc., a Delaware corporation, has announced a merger with KOITO MANUFACTURING CO., LTD, ...

Cepton's Merger with KOITO: Cash Entitlement and Nasdaq Delisting

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning!



Moving stocks this morning are clinical trial updates, an acquisition deal and a public offering.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Planet Image (NASDAQ:<a href="https://investorplace.com/stock-quotes/yibo-stock-quote/">YIBO</a>) stock is rocketing more than 79% alongside heavy pre-market trading.</li>



<li>Lipella Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/lipo-stock-quote/">LIPO</a>) shares are soaring over 58% after <a href="https://www.stocktitan.net/news/LIPO/lipella-pharmaceuticals-initiates-phase-2a-trial-for-lp-310-in-oral-kdvluw7gmnv7.html">initiating a Phase 2a clinical trial</a>.</li>



<li>Cognition Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cgtx-stock-quote/">CGTX</a>) stock is surging more than 44% with <a href="https://www.nasdaq.com/press-release/cognition-therapeutics-proof-concept-phase-2-shine-trial-demonstrates-consistent">positive Phase 2 study results</a>.</li>



<li>Tivic Health Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/">TIVC</a>) shares are gaining over 32% following a <a href="https://www.nasdaq.com/press-release/bestgrowthstockscom-issues-comprehensive-analysis-tivic-health-systems-potential">breakdown of its potential catalysts</a>.</li>



<li>Longeveron (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) stock is increasing more than 22% with the release of <a href="https://www.nasdaq.com/press-release/longeveronr-presents-study-results-clear-mind-phase-2a-clinical-trial-lomecel-btm">Phase 2a study results</a>.</li>



<li>Pineapple Financial (NYSEMKT:<a href="https://investorplace.com/stock-quotes/papl-stock-quote/">PAPL</a>) shares are rising 22% without any clear news this morning.</li>



<li>Cepton (NASDAQ:<a href="https://investorplace.com/stock-quotes/cptn-stock-quote/">CPTN</a>) stock is climbing over 19% on <a href="https://www.stocktitan.net/news/CPTN/cepton-signs-definitive-agreement-to-be-acquired-by-7cwu0k4o8p93.html">an acquisition agreement</a>.</li>



<li>Ambipar Emergency (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ambi-stock-quote/">AMBI</a>) shares are jumping more than 18% this morning.</li>



<li>BurgerFi (NASDAQ:<a href="https://investorplace.com/stock-quotes/bfi-stock-quote/">BFI</a>) stock is heading over 16% higher as it <a href="https://investorplace.com/2024/07/why-is-burgerfi-international-bfi-stock-up-71-today/">continues a recent rally</a>.</li>



<li>Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) shares are up more than 15% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>vTv Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtvt-stock-quote/">VTVT</a>) stock is plummeting over 44% after announcing the Food and Drug Administration&nbsp;(FDA) <a href="https://www.nasdaq.com/press-release/vtv-therapeutics-announces-cadisegliatin-program-type-1-diabetes-placed-clinical-hold">placed a clinical hold</a> on one of its trials.</li>



<li>CERo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cero-stock-quote/">CERO</a>) shares are diving more than 33% despite a lack of news this morning.</li>



<li>Treasure Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/tgl-stock-quote/">TGL</a>) stock is tumbling over 25% on Monday morning.</li>



<li>LuxUrban Hotels (NASDAQ:<a href="https://investorplace.com/stock-quotes/luxh-stock-quote/">LUXH</a>) shares are taking a more than 17% beating after <a href="https://www.globenewswire.com/news-release/2024/07/27/2919920/0/en/LuxUrban-Hotels-Announces-Pricing-of-Public-Offering-of-Securities.html">pricing a public offering</a>.</li>



<li>Invo Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) stock is dropping over 11% without any clear news to report.</li>



<li>Phio Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/phio-stock-quote/">PHIO</a>) shares are sliding more than 11% this morning.</li>



<li>Notable Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/ntbl-stock-quote/">NTBL</a>) stock is decreasing over 10% on Monday morning.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) shares are falling more than 9% after a Friday rally.</li>



<li>Carbon Revolution (NASDAQ:<a href="https://investorplace.com/stock-quotes/crev-stock-quote/">CREV</a>) stock is slipping over 9% after jumping Friday <a href="https://finance.yahoo.com/news/carbon-revolution-supplies-carbon-fiber-011000695.html">on a wheels deal</a>.</li>



<li>Nuwellis (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuwe-stock-quote/">NUWE</a>) shares close out our pre-market stock movers down more than 9%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-july-29th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Craig-Hallum analyst Richard Shannon maintained a Hold rating on Cepton (CPTN – Research Report) today. The company's shares closed last Friday at ...

Craig-Hallum Sticks to Their Hold Rating for Cepton (CPTN)

Maxim Group analyst Matthew Galinko has maintained their neutral stance on CPTN stock, giving a Hold rating on July 29. Matthew Galinko's rating is...

Cepton's Acquisition Outlook Amidst Setbacks: A 'Hold' Rating by Analyst Matthew Galinko

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cepton (NASDAQ:<a href="https://investorplace.com/stock-quotes/cptn-stock-quote/">CPTN</a>) just reported results for the second quarter of 2024.<ul><li>Cepton reported earnings per share of 3 cents. This was above the analyst estimate for EPS of -33 cents.</li><li>The company reported revenue of $10.43 million.</li><li>This was 5.20% worse than the analyst estimate for revenue of $11.00 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cptn-stock-earnings-cepton-for-q2-of-2024/">CPTN Stock Earnings: Cepton Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CPTN Stock Earnings: Cepton Beats EPS, Misses Revenue for Q2 2024

Cepton Non-GAAP EPS of $0.03 beats by $0.49, revenue of $10.4M beats by $7.27M

Cepton's Financial Review and Acquisition Outlook: A Hold Rating Justified

LiDAR Quarterly Insights Q2 2024 Summary

An update from Cepton ( ($CPTN) ) is now available. Cepton, Inc. is set to become an indirect subsidiary of KOITO MANUFACTURING CO., LTD. following...

Cepton Executive Compensation Terms Set Amidst Acquisition

Cepton Inc (CPTN) has disclosed a new risk, in the Share Price & Shareholder Rights category. Cepton Inc. faces significant business risks if the p...

Cepton's High-Stakes Merger: The Critical Impacts of the Koito Deal Hang in the Balance

AEVA

AMBI

CERO

CGTX

CPTN

CREV

INVO

INVZ

LAZR

LGVN

LIDR

LIPO

LUXH

MVIS

NTBL

NUWE

OUST

PAPL

PHIO

TIVC

VCNX

VTVT

YIBO

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IROH, CPTN, GVP, CBZ on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CPTN, RVNC, K, RXRX on Behalf of Shareholders

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, RVNC, CPTN on Behalf of Shareholders

Kuehn Law Encourages USAP, CPTN, NBR, and INSI Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, CPTN, NBR, INSI on Behalf of Shareholders  October 21, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CPTN, ESGR, RCM on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates YOTA, PWUP, CPTN, INSI on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, CPTN, GLYC, ARC on Behalf of Shareholders

Kuehn Law Encourages CPTN, ALTR, RCM, and WMPN Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALTR, WMPN, RCM, CPTN on Behalf of Shareholders

ALTR

ESGR

GLYC

INSI

IROH

PFIE

PWUP

RVNC

RXRX

USAP

WMPN

YOTA

Astrotech

Coda Octopus Group

Digital Ally

Electro-Sensors

Focus Universal

Frequency Electronics, Inc. - Common Stock

Frequency Electronics

Identiv

AEye

Interlink Electronics, Inc. - Common Stock

Interlink Electronics

LightPath Technologies, Inc. - Class A Common Stock

LightPath Technologies

Luna Innovations Incorporated - Common Stock

Luna Innovations

908 Devices

MultiSensor AI Holdings, Inc. - Common Stock

MultiSensor AI Holdings

Maris Tech

Research Frontiers Incorporated - Common Stock

Research Frontiers

SMX (Security Matters) Public Limited Company - Class A Ordinary Shares

SMX (Security Matters)

Sobr Safe

Sono-Tek

SaverOne 2014 Ltd. - American Depositary Shares

Saverone 2014

Unusual Machines

Universal Security Instruments, Inc. Common Stock

Universal Security

VerifyMe

Vuzix

Wrap Technologies

Zepp Health Corporation American depositary shares, each representing sixteen Class A ordinary shares

Comments

Cepton

Cepton (CPTN) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO